Development and validation of a prediction model for identifying men with intermediate- or high-risk prostate cancer for whom bone imaging is unnecessary: a nation-wide population-based study

References

• James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–1038.
   PubMed Web of Science ®Google Scholar
• Mottet N, van den Bergh RCN, Briers E, et al. EAU - ESTRO - SIOG guidelines on prostate cancer; 2017 [cited 2019 Jun 19]. Available from: https://uroweb.org/wp-content/uploads/EAU-EANM-ESUR-ESTRO-SIOG-Guidelines-on-Prostate-Cancer-2019.pdf
   Google Scholar
• National Comprehensive Cancer Network (NCCN) clinical practice guidelines in Oncology. Prostate Cancer, version 3; 2016 [cited 2019 Jun 19]. NCCN.org. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management. Clinical guideline [CG175]; 2017 [cited 2019 Jun 19]. Available from: https://www.nice.org.uk/guidance/cg175/chapter/1-Recommendations#assessment-2
   Google Scholar
• AUA. American Urological Association. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline; 2017 [cited 2019 Jun 19]. Available from: https://www.auanet.org/guidelines/prostate-cancer-clinically-localized-(2017)#x6912.
   Google Scholar
• The National Board of Health and Welfare S. Nationella riktlinjer för prostatacancer, Vetenskapligt underlag; 2018 [cited 2019 Jun 19]. Available from: https://www.socialstyrelsen.se/SiteCollectionDocuments/nr-cancer-vetenskapligt-underlag-prostatacancer.pdf
   Google Scholar
• Nationellt vårdprogram för Prostatacancer. 2019 [cited 2019 Jun 19]. Available from: https://www.cancercentrum.se/samverkan/cancerdiagnoser/prostata/vardprogram/
   Google Scholar
• Tomic K, Sandin F, Wigertz A, et al. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101–111.
   PubMed Web of Science ®Google Scholar
• Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort profile: the National Prostate Cancer Register of Sweden and prostate cancer data base Sweden 2.0. Int J Epidemiol. 2013;42(4):956–967.
   PubMed Web of Science ®Google Scholar
• Hurvich CM, Tsai CL. Regression and time series model selection in small samples. Biometrika. 1989;76(2):297–307.
   Web of Science ®Google Scholar
• Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. JCO. 2012;30(14):1715–1724.
   PubMed Web of Science ®Google Scholar
• Porten SP, Smith A, Odisho AY, et al. Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis. 2014;17(3):246–251.
   PubMed Web of Science ®Google Scholar
• Makarov DV, Loeb S, Ulmert D, et al. Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst. 2013;105(17):1306–1313.
   PubMedGoogle Scholar
• Makarov DV, Desai RA, Yu JB, et al. The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population. J Urol. 2012;187(1):97–102.
   PubMed Web of Science ®Google Scholar
• Rutledge AB, McLeod N, Mehan N, et al. A clinician-centred programme for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer. BJU Int. 2018;121(3):22–27.
   PubMedGoogle Scholar
• Prasad SM, Gu X, Lipsitz SR, et al. Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. Cancer. 2012;118(5):1260–1267.
   PubMed Web of Science ®Google Scholar
• Wondergem M, van der Zant FM, Knol RJJ, et al. Tc-HDP bone scintigraphy and (18)F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer. World J Urol. 2018;36(1):27–34.
   PubMed Web of Science ®Google Scholar
• Padhani AR, Lecouvet FE, Tunariu N, et al. Rationale for modernising imaging in advanced prostate cancer. Eur Urol Focus. 2017;3(2–3):223–239.
   PubMedGoogle Scholar
• van Leeuwen PJ, Donswijk M, Nandurkar R, et al. 68Ga PSMA PET/CT predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate and high-risk prostate cancer. BJU Int. 2019;1:62–68.
   Google Scholar
• Siva S, Bressel M, Murphy DG, et al. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74(4):455–462.
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974.
   PubMed Web of Science ®Google Scholar
• Lin Y, Mao Q, Chen B, et al. When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? A retrospective study. BMC Urol. 2017;17(1):41.
   PubMedGoogle Scholar
• KandaSwamy GV, Bennett A, Narahari K, et al. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort. BJU Int. 2017;120(5B):E59–E63.
   PubMed Web of Science ®Google Scholar
• Gabriele D, Collura D, Oderda M, et al. Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database. World J Urol. 2016;34(4):517–523.
   PubMed Web of Science ®Google Scholar
• Briganti A, Suardi N, Gallina A, et al. Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev. 2014;40(1):3–11.
   PubMed Web of Science ®Google Scholar
• McArthur C, McLaughlin G, Meddings RN. Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients. BJR. 2012;85(1012):390–394.
   Google Scholar
• Briganti A, Passoni N, Ferrari M, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol. 2010;57(4):551–558.
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Leonardo C, Franco G, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool. World J Urol. 2013;31(2):365–369.
   PubMed Web of Science ®Google Scholar
• Oesterling JE, Martin SK, Bergstralh EJ, et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA. 1993;269(1):57–60.
   PubMed Web of Science ®Google Scholar
• Salonia A, Gallina A, Camerota TC, et al. Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features. Urology. 2006;68(2):362–366.
   PubMed Web of Science ®Google Scholar
• Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(12):2114–2121.
   PubMed Web of Science ®Google Scholar
• Roach PJ, Francis R, Emmett L, et al. The impact of (68)Ga-PSMA PET/CT on management intent in prostate cancer: results of an australian prospective multicenter study. J Nucl Med. 2018;59(1):82–88.
   PubMed Web of Science ®Google Scholar
• Davidson T, Amit U, Saad A, et al. Gallium-68 prostate-specific membrane antigen PET-CT and the clinical management of prostate cancer. Nucl Med Commun. 2019;40(9):913–919.
   PubMed Web of Science ®Google Scholar